JUN and melanoma: Intuitively, the half-life of c-Jun was shortened after AIL treatment (Fig. 3I and Additional file 2: Fig. S4F), and we also observed that MG-132, a proteasome inhibitor, could rescue the downregulation of c-Jun in melanoma cells after AIL treatment (Fig. 3J, Additional file 2: Fig. S4G and Fig. S5G).